Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.17−0.43 (-4.06%)
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
Corvus Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Corvus Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$44.53M. For fiscal 2025 it was -$32.80M. The highest annual figure on record is -$11.33M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.80M | – |
| FY2024 | Dec 31, 2024 | -$25.42M | – |
| FY2023 | Dec 31, 2023 | -$23.94M | – |
| FY2022 | Dec 31, 2022 | -$27.02M | – |
| FY2021 | Dec 31, 2021 | -$36.72M | – |
| FY2020 | Dec 31, 2020 | -$34.78M | – |
| FY2019 | Dec 31, 2019 | -$37.32M | – |
| FY2018 | Dec 31, 2018 | -$40.99M | – |
| FY2017 | Dec 31, 2017 | -$46.21M | – |
| FY2016 | Dec 31, 2016 | -$27.86M | – |
| FY2015 | Dec 31, 2015 | -$11.33M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.43M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.61M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.99M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$10.89M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.98M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.77M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.71M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.75M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.69M | – |
See a number that looks wrong?